Trianni Inc., of San Francisco, agreed to license the use of its Trianni Mouse, a monoclonal antibody discovery platform, to Janssen Biotech Inc., a unit of Johnson & Johnson, of New Brunswick, N.J. The platform provides access to a complete human antibody repertoire optimized for the rapid isolation of fully human therapeutics.